Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $78,454.50 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $16.26, for a total transaction of $78,454.50. Following the transaction, the director now owns 3,702,595 shares in the company, valued at $60,204,194.70. The trade was a 0.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tyra Biosciences Stock Down 2.4 %

Shares of Tyra Biosciences stock traded down $0.38 during trading hours on Monday, reaching $15.50. 170,982 shares of the stock traded hands, compared to its average volume of 264,918. Tyra Biosciences, Inc. has a one year low of $12.48 and a one year high of $29.60. The firm has a market capitalization of $784.35 million, a price-to-earnings ratio of -9.63 and a beta of 1.04. The company has a 50 day moving average price of $15.38 and a 200 day moving average price of $19.12.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Tyra Biosciences during the 4th quarter valued at approximately $149,000. JPMorgan Chase & Co. boosted its position in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares during the period. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences in the third quarter worth approximately $278,000. Barclays PLC raised its position in shares of Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares during the period. Finally, State Street Corp raised its position in shares of Tyra Biosciences by 4.4% during the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after purchasing an additional 16,248 shares during the period. Institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on TYRA. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, January 13th. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, UBS Group began coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.